Clinical trials in Hoofddorp – page 114

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Hoofddorp at a glance

1 940

clinical trials

Research sites1

Quick filters

1 940 trials in Hoofddorp

Open in trial search

Inflammatory bowel disease

Not recruiting

Study Comparing Infliximab Alone or with Immunosuppressive Drugs for Moderate to Severe Crohn's Disease Patients

Registered drugNo placebo

Study Comparing Infliximab Alone or with Immunosuppressive Drugs for Moderate to Severe Crohn's Disease Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Doxorubicin Hydrochloride
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Encephalitis autoimmune

Not recruiting

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Neuromyelitis optica spectrum disorder

Not recruiting

Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo

Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Imlifidase
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Radboud universitair medisch centrum Stichting

Contact Research Centre

Vulval cancer+1

Not recruiting

Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma

Registered drugNo placebo

Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Leids Universitair Medisch Centrum (LUMC)

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Study on the Safety and Effectiveness of Binimetinib, Lapatinib, and Vinorelbine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Binimetinib, Lapatinib, and Vinorelbine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Dilated cardiomyopathy

Not recruiting

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:AB-1002
Sponsor:Askbio Inc.

Contact Research Centre

Encephalopathy neonatal+1

Not recruiting

Study on the Effect of Allopurinol and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drug

Study on the Effect of Allopurinol and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drug

The Netherlands

Participants:0–17 years
Substances:Allopurinol Sodium
Sponsor:Universitaetsklinikum Tuebingen AöR

Contact Research Centre

Burkitt's lymphoma

Not recruiting

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

Advanced/Metastatic Breast Cancer Treatments
Urothelial Cancer Therapies
Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

B-Cell Lymphoma Treatments
Myelofibrosis Therapies
Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

Weight Management Interventions
Surgical Techniques
Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the Netherlands All countries